A recent Phase II study has demonstrated that oral FTY720 is effective in reducing disease activity in relapsing multiple sclerosis with a favorable adverse-effect profile. These results are awaiting confirmation in the three ongoing Phase III clinical trials Expert Review of Neurotherapeutics
This review summarizes the effects of eNOS on the regulation of cerebral blood flow, hemostasis, inflammation, angiogenesis as well as neurogenesis. Future Neurology
Young adults with ADHD present unique challenges that require close attention to each individual. How can you tailor treatment in this difficult population? What strategies improve adherence and outcomes? Medscape Psychiatry & Mental Health
